Last update 19 Sep 2024
ZX-101A
Last update 19 Sep 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Related
5
Clinical Trials associated with ZX-101AA Dose-Escalation and Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ZX-101A Monotherapy in Patients With Advanced Solid Tumors
一项评价ZX-101A 单药在晚期实体瘤患者中的安全性、耐受性、药代动力学、药效学和初步疗效的开放性剂量递增和扩展Ⅰ/Ⅱa 期临床研究
[Translation] An open-label, dose-escalation and expansion Phase I/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of ZX-101A monotherapy in patients with advanced solid tumors
A Phase I/II Study Evaluating ZX-101A in Patients With Relapsed/Refractory Hematological Malignancies
100 Clinical Results associated with ZX-101A
Login to view more data
100 Translational Medicine associated with ZX-101A
Login to view more data
100 Patents (Medical) associated with ZX-101A
Login to view more data
100 Deals associated with ZX-101A
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Mar 2022 | |
| Small Lymphocytic Lymphoma | Phase 2 | CN | 27 Jan 2022 | |
| B-Cell Lymphoma | Phase 2 | CN | 17 Jan 2022 | |
| Peripheral T-Cell Lymphoma | Phase 2 | CN | 17 Jan 2022 | |
| Hematologic Neoplasms | Phase 2 | CN | 10 Dec 2021 | |
| Chronic Lymphocytic Leukemia | Phase 2 | US | 07 Aug 2020 | |
| Non-Hodgkin Lymphoma | Phase 2 | US | 07 Aug 2020 | |
| Solid tumor | Discovery | CN | 14 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 6 | bdaroqbbkf(kjsaqavbhg) = hfebbbirap ibpsbqoyyp (gwwarovwvk ) | - | 01 Jul 2021 | |||
Anti-PD1 antibody | bdaroqbbkf(kjsaqavbhg) = sksbxwvbng ibpsbqoyyp (gwwarovwvk ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free